secwatch / observer
8-K filed November 26, 2025, 6:59 PM ET ticker NEPH CIK 0001196298
other material confidence high sentiment positive materiality 0.70

Nephros signs exclusive license & supply deal with Medica; min purchases €4.98M-€6.3M/yr through 2030

NEPHROS INC

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NEPHROS INC entered into License and Supply Agreement with Medica S.p.A. valued at minimum annual aggregate purchases from Medica of €4,976,000, €5,349,000, €5,750,000, €6,000,000 and (effective 2025-11-21).

Action
entry
Agreement
license
Counterparty
Medica S.p.A.
Value
minimum annual aggregate purchases from Medica of €4,976,000, €5,349,000, €5,750,000, €6,000,000 and
Effective
2025-11-21
Exact text from the filing
On November 21, 2025, Nephros, Inc. (the “Company”) entered into a license and supply agreement (the “License and Supply Agreement”) with Medica S.p.A. (“Medica”), an Italy-based medical product manufacturing company, for the marketing and sale of certain filtration products based upon Medica’s proprietary Medisulfone ultrafiltration technology in conjunction with the Company’s filtration products (collectively, the “Products”), and to engage in an exclusive supply arrangement for the Products.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NEPHROS INC terminated Prior Agreement with Medica S.p.A. (effective 2025-11-21).

Action
termination
Agreement
license
Counterparty
Medica S.p.A.
Effective
2025-11-21
Exact text from the filing
The License and Supply Agreement supersedes and replaces that certain License and Supply Agreement, dated December 11, 2023 (the “Prior Agreement”), between the Company and Medica, which Prior Agreement was terminated by the parties upon entry into the License and Supply Agreement.
View on SEC.gov

Browse all material agreements →

NEPHROS INC filing history →

Source: SEC EDGAR
accession 0001493152-25-025155
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.